# 1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;H69del;V70del

# 1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;Y144del

# 1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;N501Y

# No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;A570D

# 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;P681H

# 1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;T716I

# 2x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;S982A

# 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;D1118H

# This variant combination (representing B.1.1.7 aka Alpha) showed no change in Spike binding 
# (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.28x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of 
# Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;H69del;V70del;Y144del;N501Y;A570D;P681H;T716I;S982A;D1118H

# 1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# Compare to varied binding in full Spike variant complements for major lineages
# containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma).
# 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Compare to varied binding in full Spike variant complements for major lineages
# containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;L18F

# 1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;D80A

# 1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;D215G

# 1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;L242del;A243del;L244del

# 1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;R246I

# 1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;K417N

# 1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;E484K

# 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;A701V

# This variant combination (representing B.1.351 aka Beta) 
# showed a 1.28x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.
# It shows a 1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;L18F;D80A;N501Y;D215G;L242del;A243del;L244del;R246I;K417N;E484K;A701V

# 1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.
# 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;T20N

# 1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;P26S

# 1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;D138Y

# 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;R190S

# 1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;K417T

# 1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;H655Y

# 1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;T1027I

# This variant combination (representing P.1 aka Gamma) 
# showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;H655Y;T1027I

# 1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;L5F

# 1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;T95I

# No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;D253G

# This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative 
# to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;L5F;T95I;D253G;E484K;A701V

# 1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;S13I

# 1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;W152C

# 1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.
# 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;L452R

# This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding 
# (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.
# [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation 
# against L452R effects]
# 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
D614G;S13I;W152C;L452R

# This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative 
# to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  
# 1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# [exact variant list not provided in manuscript, is inferred fro common knowledge]
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
L452R;E484Q;D614G	

# This variant combination (representing lineage B.1.617.1) showed a 1.79x decrease in Spike binding (relative to D614G alone) 
# by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 
# 1.64x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# [exact variant list not provided in manuscript, is inferred and 
# represents minimal set agreed upon commonly]
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
G142D;E154K;L452R;E484Q;D614G;P681R;Q1071H

# This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.64x decrease in Spike binding (relative to D614G alone) 
# by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  
# 1.89x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.
# [exact variant list not provided in manuscript, is inferred and 
# represents minimal set agreed upon commonly]
# Gong et al. (2021) http://doi.org/10.1101/2021.08.04.455140 [Preprint (BioRxiv)]
T19R;E156del;F157del;R158G;L452R;T478K;D614G;P681R;D950N
